Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 3/20 | 0.49 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.49 |
| ▸ | CTSS | P25774 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2495376 | 0.88 | CPB1 (0.47) | KLK7KLK5CTSSCTSLPTGER4 | |
| SCHEMBL2845514 | 0.85 | CTSS (0.48) | KLK7KLK5CTSSCTSLPTGER4 | |
| SCHEMBL2845533 | 0.85 | CTSS (0.48) | KLK7KLK5CTSSCTSLPTGER4 | |
| SCHEMBL12193390 | 0.81 | PTGER4 (0.54) | CTSSCTSLPTGER4ITGB3 | |
| SCHEMBL5652265 | 0.79 | PTGER4 (0.68) | CTSSCTSLPTGER4 | |
| SCHEMBL12193694 | 0.78 | CTSS (0.46) | KLK7KLK5CTSSCTSLPTGER4 | |
| SCHEMBL5654995 | 0.78 | PTGER4 (0.59) | CTSSCTSLPTGER4 | |
| SCHEMBL5823969 | 0.77 | PTGER4 (0.47) | CTSSCTSLPTGER4 | |
| SCHEMBL5653073 | 0.77 | PTGER4 (0.49) | CTSSCTSLPTGER4 | |
| SCHEMBL5653223 | 0.77 | PTGER4 (0.51) | CTSSCTSLPTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030489-B2 | Ornithine derivative | ASTELLAS PHARMA INC. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20100216803-A1 | ORNITHINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-08-26 | — | — | US | disclosed |
| EP-2141147-A1 | ORNITHINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216803-A1 | ORNITHINE DERIVATIVE | PTGER4, OXER1, ODC1 | KLK7 2470/4885KLK5 1391/4885CTSS 4049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.